Washington:
People who received Johnson & Johnson’s Covid-19 vaccine could advantage from a booster dose of Pfizer or Moderna, preliminary benefits of a US study published Wednesday showed.
The study, funded by the National Institutes of Health (NIH), was eagerly awaited in the United States mainly because it looked at the possibility of “mixing” vaccines — making use of a various vaccine than the initial doses for the booster shot — which is not at the moment permitted in the nation.
The study was carried out on 458 adults who had been vaccinated with one of 3 US-authorized brands (Pfizer, Moderna or J&J) for at least 12 weeks.
These 3 groups have been every single divided into 3 new groups to get one of the obtainable vaccines as a booster. The nine groups consisted of about 50 men and women every single.
Researchers then analyzed antibody levels 15 days soon after the booster shot.
For men and women initially inoculated with J&J, antibody levels have been 4 instances larger soon after a J&J booster, 35 instances larger soon after a Pfizer booster and 76 instances larger soon after a Moderna booster.
And antibody levels for these who had initially received Moderna shots have been larger “irrespective of the booster vaccine administered,” when compared with these who had initially received Pfizer or J&J, the study stated.
Additionally, “no safety concerns were identified” soon after booster doses have been administered, it discovered.
The study, which has not however been peer-reviewed, has a number of limitations, on the other hand.
The quantity of participants was smaller, and the immune response could evolve more than time, beyond the 15 days observed for the duration of the study.
“Important not to get too carried away with the findings,” tweeted Peter Hotez, a professor at Baylor College of Medicine.
Results from trials on a second J&J booster shot carried out by the organization itself have been “impressive,” he stated.
The NIH study really should fuel discussions by a US Food and Drug Administration (FDA) specialist committee, which is scheduled to look at applications for a booster dose from Moderna and J&J on Thursday and Friday, respectively.
A booster from Pfizer has currently been authorized in the United States for particular populations, such as men and women aged 65 or older, adults with higher-threat health-related circumstances and these in jobs exactly where they are often exposed to the coronavirus.
()